<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-KEN25213-TC6-S6-GP4"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S1587 IS: Fair Prescription Drug Prices for Americans Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-05-05</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 1587</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250505">May 5, 2025</action-date><action-desc><sponsor name-id="S399">Mr. Hawley</sponsor> (for himself and <cosponsor name-id="S422">Mr. Welch</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To require that the retail list price for certain prescription drugs and biological products may not exceed the average retail list price for the drug or biological product among certain nations.</official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause"><section section-type="section-one" id="S1"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Fair Prescription Drug Prices for Americans Act</short-title></quote>.</text></section><section commented="no" display-inline="no-display-inline" id="idf49c4224f2f3422cb7d7b3e8e960a060"><enum>2.</enum><header>International reference pricing for prescription drugs and biological products</header><subsection commented="no" display-inline="no-display-inline" id="idba76deebbfab4178bb8d1fc8e448c3b3"><enum>(a)</enum><header display-inline="yes-display-inline">Definitions</header><text display-inline="yes-display-inline">In this section:</text><paragraph commented="no" display-inline="no-display-inline" id="id4f6f42009cfd442aa156341765a157b7"><enum>(1)</enum><header>Biological product</header><text>The term <term>biological product</term> means a biological product licensed under subsection (a) or (k) of section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>). </text></paragraph><paragraph id="idb817d96f24b7421b9dc9340f2a186ab6"><enum>(2)</enum><header>Drug</header><text>The term <term>drug</term> means a drug approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>).</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id900733fe5367408984365261793d69a7"><enum>(3)</enum><header>Secretary</header><text>The term <term>Secretary</term> means the Secretary of Health and Human Services. </text></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id6eb52af945b546d6a10a508f31a79248"><enum>(b)</enum><header display-inline="yes-display-inline">Cap on retail list price of prescription drugs and biological products</header><text display-inline="yes-display-inline">The retail list price in the United States for a drug or a biological product may not exceed the average retail list price for the drug or biological product among Canada, France, Germany, Italy, Japan, and the United Kingdom, as calculated under subsection (c).</text></subsection><subsection id="idebb0235de1e449b4bf65421348e59861"><enum>(c)</enum><header>Calculation of average retail list price</header><text display-inline="yes-display-inline">The Secretary shall calculate on an annual basis the average retail list price for each drug and biological product sold in Canada, France, Germany, Italy, Japan, and the United Kingdom, through a combination of data reported by manufacturers of drugs and biological products under subsection (e) and data obtained through review of publicly filed materials by manufacturers of drugs and biological products in such countries. </text></subsection><subsection id="id5868439340134a36a8191294816992fc"><enum>(d)</enum><header>Civil monetary penalty</header><paragraph commented="no" display-inline="no-display-inline" id="id7afd8ffb316b46b88c551f9b6a4e5ec9"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Any manufacturer that violates subsection (b) with respect to a drug or biological product shall be subject to a civil monetary penalty imposed by the Secretary in amount equal to the product obtained by multiplying—</text><subparagraph commented="no" display-inline="no-display-inline" id="id8729f08d62fb470891751e94262805b8"><enum>(A)</enum><text display-inline="yes-display-inline">the difference between—</text><clause commented="no" display-inline="no-display-inline" id="ida2b8d7c6d944460f85ddb52a8d4d83f1"><enum>(i)</enum><text display-inline="yes-display-inline">the list price for the drug or biological product sold in the United States; and </text></clause><clause commented="no" display-inline="no-display-inline" id="ideca2a03d77c5414ea3207a8386a8eb2f"><enum>(ii)</enum><text display-inline="yes-display-inline">the average retail list price for the drug or biological product sold in Canada, France, Germany, Italy, Japan, and the United Kingdom, as calculated under subsection (c); and</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ida549a5f4cb5c4da7aba8df03825b7875"><enum>(B)</enum><text>10.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id8db1cddd40d14dfabca6fd99d9f8a712"><enum>(2)</enum><header>Requirement</header><text>The amount of a civil monetary penalty under paragraph (1) shall be calculated and charged for each unit of drug or biological product sold. </text></paragraph></subsection><subsection id="id919d3cadade4434896710289523df2ea"><enum>(e)</enum><header>Data collection</header><text display-inline="yes-display-inline">Each manufacturer of a drug or biological product shall submit to the Secretary on an annual basis—</text><paragraph commented="no" display-inline="no-display-inline" id="ide0366cab5fdf431e9dd9ec168773ffb8"><enum>(1)</enum><text display-inline="yes-display-inline">the list price for the drug or biological product sold in the United States; and</text></paragraph><paragraph id="idf4fe900fd5d842218a87bc805b6c8a24"><enum>(2)</enum><text>the list price for the drug or biological product sold in each of Canada, France, Germany, Italy, Japan, and the United Kingdom.</text></paragraph></subsection><subsection id="id1b19edc3efbb48a389c33f8d1a923fe7"><enum>(f)</enum><header>Guidance and regulations</header><text>The Secretary shall issue guidance and promulgate regulations to implement this section.</text></subsection></section></legis-body></bill> 

